Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

PURPOSE: In chronic lymphocytic leukemia (CLL), TP53 deletion/mutation is strongly associated with an adverse outcome and resistance to chemotherapy-based treatment. In contrast, TP53 defects are not associated with resistance to the anti-CD52 monoclonal antibody alemtuzumab or methylprednisolone....

Full description

Bibliographic Details
Main Authors:	Pettitt, A, Jackson, R, Carruthers, S, Dodd, J, Dodd, S, Oates, M, Johnson, G, Schuh, A, Matutes, E, Dearden, C, Catovsky, D, Radford, J, Bloor, A, Follows, G, Devereux, S, Kruger, A, Blundell, J, Agrawal, S, Allsup, D, Proctor, S, Heartin, E, Oscier, D, Hamblin, T, Rawstron, A, Hillmen, P
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Catovsky, D, et al.
Published: (2006)

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2004)

Prognostic factors in the UK LRF CLL4 trial
by: Oscier, D, et al.
Published: (2006)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2005)

A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group)
by: Hillmen, P, et al.
Published: (2006)

Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
by: Lin, K, et al.
Published: (2012)

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
by: Catovsky, D, et al.
Published: (2007)

UK experience of Ofatumumab in refractory B-CLL
by: Varghese, A, et al.
Published: (2011)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
by: Dearden, C, et al.
Published: (2011)

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
by: Gonzalez, D, et al.
Published: (2011)

Gender as a prognostic factor in CLL. Biological pointers to the improved outcome of women.
by: Catovsky, D, et al.
Published: (2004)

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion
by: Gonzalez, D, et al.
Published: (2008)

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL
by: Munir, T, et al.
Published: (2014)

Early results from LRF CLL4: A UK multicenter randomized trial
by: Catovsky, D, et al.
Published: (2005)

The lack of survival differences in randomised trials in CLL may be related to the effect of second line therapies. A report from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2006)

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.
by: Oscier, D, et al.
Published: (2010)

Comparison of oral and intravenous fludarabine in the LRF CLL4 trial.
by: Hillmen, P, et al.
Published: (2005)

Drug sensitivity by TRAC (DISC) assay as a prognostic factor for patient response in untreated CLL: Results from the UK LRF CLL4 trial.
by: Bosanquet, A, et al.
Published: (2006)

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.
by: Oscier, D, et al.
Published: (2012)

The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial
by: Dearden, C, et al.
Published: (2007)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2006)

Preliminary results of the UK Medical Research Council trial in chronic lymphocytic leukaemia - CLL3
by: Catovsky, D, et al.
Published: (1998)

S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
by: P. Hillmen, et al.
Published: (2022-06-01)

UK Medical Research Council CLL3 - A randomized trial of the addition of epirubicin to standard chlorambucil treatment.
by: Catovsky, D, et al.
Published: (2000)

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.
by: Sellick, G, et al.
Published: (2008)

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
by: Matutes, E, et al.
Published: (2013)

The use of individualized tumor response testing in treatment selection: Second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry
by: Matutes, E, et al.
Published: (2013)

Comparison of ZAP-70, IgVH gene mutational status and CD38 in CLL patients requiring therapy: Preliminary report from the UKCLL IV trial.
by: Orchard, J, et al.
Published: (2003)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
by: Marco Montillo, et al.
Published: (2008-03-01)

Quality of life in the UK LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Else, M, et al.
Published: (2006)

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
by: Hale, G, et al.
Published: (2004)

P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX.
by: A. Rawstron, et al.
Published: (2022-06-01)

Quality of life in the LRF CLL4 trial.
by: Else, M, et al.
Published: (2005)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
by: Lundin, J, et al.
Published: (2001)

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)
by: Hillmen, P, et al.
Published: (2014)

Baseline characteristics associated with quality of life in CLL patients requiring therapy
by: Else, M, et al.
Published: (2007)

Incidence of hemolytic anemia after chemotherapy in the CLL4 trial. A possible protective role for fludarabine plus cyclophosphamide.
by: Catovsky, D, et al.
Published: (2004)

ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
by: Muthusamy, A, et al.
Published: (2011)

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
by: Guièze, R, et al.
Published: (2015)

In vivo 'purging' of residual disease in CLL with Campath-1H.
by: Dyer, M, et al.
Published: (1997)